Please click on the banner image above to watch the dialogue.
“What we understand is that these diseases begin very early in life. They don’t suddenly occur when you’re in your seventies or eighties or nineties, they’ve begun years ago. And this model would begin to detect some of these (disease causing) processes, so we could intervene.” – William N. Hait
Episode II of the “Dialogues on Healthy Aging” features William N. Hait, Global Head, Johnson & Johnson External Innovation with moderation by Karen Tkach Tuzman, Senior Editor and Head of Discovery & Preclinical Development, BioCentury.
Key discussions around:
– How is industry’s approach to healthy aging and how is it evolving?
– What biological pathways are emerging as key sources of targets for aging related diseases, and what kinds of technologies are of poised to help address those pathways?
– What approaches are most promising for early intercepting and preventing aging-related diseases?
Dr. William N. Hait leads the external sourcing and creation of transformational innovation to help Johnson & Johnson achieve its mission to change the trajectory of health for humanity. He works on building an enterprise-wide external R&D pipeline, creating innovative solutions that utilize J&J’s excellence in pharmaceuticals, medical devices and consumer products. His team strives to identify disruptive technologies and cutting-edge early innovations in disease areas of emphasis at J&J, to eliminate disease through prevention, interception and cures.
Dr. Hait joined J&J in 2007 and served as Global Therapeutic Area Head for Oncology from 2009 to 2011, and then as Global Head, Janssen Research & Development, from 2011 through 2018. Before that, he was the founding Director of The (Rutgers) Cancer Institute of New Jersey. From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey -- Robert Wood Johnson Medical School.
As Head of Discovery and Preclinical Research, Karen guides BioCentury’s coverage of emerging biology and technologies. She has written extensively about immunology, synthetic biology and data science, covering innovative breakthroughs in industry and academia, and dissecting trends in company formation and investments around new science. She coordinates activities and interactions with BioCentury’s Scientific Advisory Board.
Karen joined BioCentury in 2015 after a postdoctoral research fellowship in Stanford University's Department of Chemical and Systems Biology. She holds a Ph.D. in Immunology from Weill Cornell Medicine and a B.A. in Molecular and Cell Biology from the University of California Berkeley.